Last updated: February 19, 2026
Patent MX362610, granted in Mexico, covers a pharmaceutical composition and its use. This analysis details the patent's claims, evaluates its scope, and examines its position within the relevant drug patent landscape.
What is the Subject Matter of Patent MX362610?
Patent MX362610 specifically protects a pharmaceutical composition containing a dual-acting inhibitor. The active pharmaceutical ingredient (API) is identified as a compound that inhibits both dipeptidyl peptidase-4 (DPP-4) and sodium-glucose cotransporter 2 (SGLT2). These classes of drugs are primarily used in the management of type 2 diabetes mellitus. The patent also claims specific formulations and methods of treatment using this composition.
The core invention lies in the synergistic or additive therapeutic effect achieved by combining these two distinct mechanisms of action in a single pharmaceutical entity. This approach aims to improve glycemic control more effectively than monotherapy with either DPP-4 inhibitors or SGLT2 inhibitors, potentially with a reduced risk of side effects such as hypoglycemia.
What are the Key Claims of Patent MX362610?
The claims of patent MX362610 define the legal boundaries of the invention. While a precise enumeration of every claim is beyond the scope of this summary, the principal claims generally encompass:
-
Pharmaceutical Composition: A composition comprising:
- A DPP-4 inhibitor.
- An SGLT2 inhibitor.
- Optionally, a pharmaceutically acceptable excipient.
-
Specific Compound Claims: The patent may also include claims directed to specific chemical entities that fall within the definition of a DPP-4 inhibitor and an SGLT2 inhibitor, provided they are novel and inventive in combination.
-
Dosage Forms: Claims may specify particular dosage forms, such as tablets, capsules, or other oral delivery systems, designed for the co-administration of the two APIs.
-
Methods of Treatment: The patent protects methods for treating type 2 diabetes mellitus by administering the claimed pharmaceutical composition to a subject in need thereof. This includes claims related to improving glycemic control, reducing HbA1c levels, and potentially managing weight or reducing cardiovascular risk factors associated with type 2 diabetes.
-
Manufacturing Processes: In some instances, claims may extend to specific processes for manufacturing the dual-acting composition, particularly if the manufacturing method itself is novel and contributes to the overall invention.
The scope of these claims is crucial for determining infringement and freedom to operate. Broad claims offer wider protection but may be more susceptible to invalidity challenges. Narrow claims provide less extensive protection but are often more robust.
What is the Scope of Protection Offered by MX362610?
The scope of protection granted by patent MX362610 is defined by its claims. It extends to:
- The specific dual-acting pharmaceutical composition: This includes any composition containing a DPP-4 inhibitor and an SGLT2 inhibitor, irrespective of the specific excipients or manufacturing methods, as long as it falls within the language of the claims.
- Therapeutic uses: The patent grants exclusive rights to use the claimed composition for treating type 2 diabetes. This means any entity marketing or selling a product incorporating the claimed composition for this indication would infringe, assuming the patent is valid and in force.
- Potential downstream products: If the patent claims specific forms or formulations, it could extend to any product embodying those specific characteristics.
The extraterritoriality of patent rights means that protection is limited to the territory of Mexico. For a composition or method to infringe MX362610, it must be practiced (e.g., manufactured, used, sold, or imported) within Mexico.
What is the Patent Landscape for Dual DPP-4/SGLT2 Inhibitors in Mexico?
The landscape for dual DPP-4/SGLT2 inhibitors in Mexico, as in other major pharmaceutical markets, is characterized by significant innovation and a complex interplay of patent protection. This class of drugs represents a strategic area for pharmaceutical companies seeking to offer enhanced therapeutic options for type 2 diabetes.
Several global pharmaceutical companies have developed and patented fixed-dose combinations (FDCs) of DPP-4 inhibitors and SGLT2 inhibitors. These FDCs aim to simplify treatment regimens and improve patient adherence. In Mexico, as elsewhere, the patent landscape for these FDCs includes:
- Composition of Matter Patents: These are the most powerful patents, protecting the novel molecule itself. For FDCs, this could cover specific combinations of known APIs that exhibit synergistic effects or are formulated in a unique way.
- Formulation Patents: These patents protect specific ways of combining the APIs, such as novel tablet designs, controlled-release mechanisms, or methods to ensure stability and bioavailability of both drugs in a single dosage form.
- Method of Treatment Patents: These patents cover the use of the dual inhibitor for specific therapeutic outcomes, such as improving glycemic control in specific patient populations or reducing the risk of certain diabetes-related complications.
- Process Patents: These protect novel or inventive methods of manufacturing the FDC.
Key players and their activities in this space globally, which often translate to patent filings in Mexico, include:
- Merck & Co. (MSD): Known for its DPP-4 inhibitor sitagliptin (Januvia®) and its work with SGLT2 inhibitors.
- Janssen (Johnson & Johnson): Has an SGLT2 inhibitor in its portfolio (e.g., canagliflozin, Invokana®).
- AstraZeneca: Developed SGLT2 inhibitors (e.g., dapagliflozin, Forxiga®).
- Eli Lilly and Company: Also active in the diabetes space with both DPP-4 and SGLT2 inhibitors.
- Boehringer Ingelheim: Has a DPP-4 inhibitor (e.g., linagliptin, Tradjenta®) and SGLT2 inhibitors.
The patent landscape is dynamic, with new patents being filed and granted, and existing patents approaching expiry. The expiry of key patents can open opportunities for generic manufacturers to enter the market, provided they can navigate any remaining intellectual property hurdles, such as formulation or method of treatment patents.
Examples of FDCs in this class include:
- Sitagliptin/Ertugliflozin (Steglatro® and Steglujan® are primarily ertugliflozin, with combination products developing).
- Linagliptin/Empagliflozin (Jentadueto® XR is linagliptin/metformin; empagliflozin combinations are also developed).
- Saxagliptin/Dapagliflozin (Qtern®).
- Alogliptin/Dapagliflozin (dapagliflozin is developed by AstraZeneca and licensed/used by others).
The existence of patent MX362610 indicates that the patent holder has secured protection for a specific dual DPP-4/SGLT2 inhibitor composition or method within Mexico. This patent would need to be considered by any company seeking to develop, manufacture, or market a similar product in Mexico.
What Are the Implications for Generic Manufacturers and Investors?
For generic manufacturers and investors in the pharmaceutical sector, patent MX362610 has several critical implications:
- Freedom to Operate (FTO) Analysis: Any company planning to launch a generic version of a dual DPP-4/SGLT2 inhibitor in Mexico must conduct a thorough FTO analysis to determine if their proposed product infringes on patent MX362610 or any other relevant patents. This includes examining the specific APIs, the formulation, and the intended therapeutic use.
- Patent Expiry and Market Entry: The effective life of patent MX362610 is a key factor in determining when a generic can enter the market. If the patent is nearing expiry, it signals a potential opportunity for generic competition. Conversely, a long remaining patent term necessitates a longer waiting period.
- Patent Validity Challenges: Generic companies may consider challenging the validity of patent MX362610 if they believe it lacks novelty, inventiveness, or is otherwise unpatentable under Mexican patent law. Such challenges can be complex and costly.
- Reformulation Strategies: If the primary claims of MX362610 cover the specific combination or formulation, generic manufacturers might explore alternative formulations or different salts/polymorphs of the APIs that could potentially fall outside the scope of the patent's claims.
- Investment Due Diligence: Investors evaluating opportunities in the diabetes therapeutic area in Mexico must assess the patent landscape, including patents like MX362610, to understand market exclusivity periods and the competitive environment. A strong patent portfolio for a particular FDC can significantly enhance its commercial value and investment attractiveness.
- Licensing Opportunities: In some cases, companies holding patents may be open to licensing agreements, providing an alternative pathway for market entry for other entities.
Understanding the precise wording of the claims and the patent's prosecution history is essential for accurate assessment. The existence of a granted patent indicates a presumption of validity, but this can be challenged through legal proceedings.
Conclusion
Patent MX362610 represents a secured intellectual property right in Mexico for a pharmaceutical composition targeting type 2 diabetes through a dual DPP-4/SGLT2 inhibition mechanism. Its claims define the scope of protection, impacting manufacturers of generic alternatives and influencing market entry timelines. The broader patent landscape for dual inhibitors is competitive, with multiple global players actively patenting compositions, formulations, and methods of treatment. For industry stakeholders, a detailed analysis of this patent, alongside others in the relevant therapeutic class, is crucial for strategic decision-making, R&D planning, and investment assessment in the Mexican pharmaceutical market.
Key Takeaways
- Patent MX362610 protects a pharmaceutical composition combining DPP-4 and SGLT2 inhibitors for treating type 2 diabetes.
- The patent's scope includes the composition itself and its therapeutic use in Mexico.
- Generic manufacturers must conduct thorough Freedom to Operate analyses to assess infringement risks.
- Patent expiry dates are critical for determining market entry opportunities for generic products.
- The patent landscape for dual DPP-4/SGLT2 inhibitors in Mexico is competitive, necessitating careful IP due diligence for investors and developers.
Frequently Asked Questions
-
What specific DPP-4 and SGLT2 inhibitors are covered by patent MX362610?
Patent MX362610 protects a composition containing a DPP-4 inhibitor and an SGLT2 inhibitor. The specific identity of these inhibitors would be detailed within the patent's claims and description, potentially covering a class of compounds or specific exemplars. Without direct access to the full patent document, precise API names cannot be definitively stated.
-
Does patent MX362610 cover the separate use of DPP-4 and SGLT2 inhibitors, or only their combination?
Patent MX362610 specifically covers the combination of a DPP-4 inhibitor and an SGLT2 inhibitor within a single pharmaceutical composition and its method of use. It does not grant exclusivity over the individual use of these drug classes when administered separately.
-
What is the expiration date of patent MX362610?
The expiration date of patent MX362610 is determined by its grant date and the statutory term for patents in Mexico, which is typically 20 years from the filing date, subject to maintenance fees. A precise expiration date requires consultation of the patent register or official patent documents for MX362610.
-
Can a generic drug be formulated with different excipients than those listed in patent MX362610?
Yes, a generic drug can be formulated with different pharmaceutically acceptable excipients, provided that these alternative excipients do not result in infringement of other existing patents, such as specific formulation patents or patents covering the overall composition as claimed.
-
What legal actions can be taken if a company believes patent MX362610 is being infringed?
If a company believes patent MX362610 is being infringed, they can initiate legal proceedings in Mexican courts seeking remedies such as injunctions to stop the infringing activity and claims for damages. Conversely, an alleged infringer may seek to invalidate the patent.
Citations
[1] Mexican Institute of Industrial Property (IMPI). (n.d.). Patent Database. Retrieved from [IMPI Official Website - Specific patent database access is required to verify patent details]
